| Literature DB >> 31760454 |
P Palcu1, S Munce2, S B Jaglal2,3,4,5, S Allin4, J A Chishtie5, A Silverstein6, S Kim7,8.
Abstract
This study sought to understand patient experiences, benefits, and challenges to osteoporosis care delivered virtually by telemedicine. Telemedicine bridges the access gap to specialized osteoporosis care in remote areas. Improving coordination of investigations, access to allied health members, and future initiatives may improve osteoporosis-related morbidity and mortality in this population.Entities:
Keywords: Mixed methods; Osteoporosis care; Patient experience; Telemedicine; Virtual
Year: 2019 PMID: 31760454 PMCID: PMC7010610 DOI: 10.1007/s00198-019-05182-5
Source DB: PubMed Journal: Osteoporos Int ISSN: 0937-941X Impact factor: 4.507
Fig. 1A flowchart representing a joint display of quantitative results, qualitative results, and the synthesis of the qualitative and quantitative results for the themes of quality of care, access to care, and coordination of care
Telemedicine visit encounter information of survey responders versus non-responders (after excluding duplicate entries, deceased participants, or those never seen in the osteoporosis telemedicine program). Date of last physician encounter is categorized as “Recent” if the participant was last seen within 1 year of the survey mail-out from 2017 to 2018, “Intermediate” if last seen between 2015 and 2016, and “Distant” if last seen between 2013 and 2014. Allied health encounter data is presented if the participant had a minimum of one visit encounter with an allied health team member and is also shown according to date of last physician encounter
| Telemedicine encounter information | Total surveys (after exclusions) | |
|---|---|---|
| Responders ( | Non-responders ( | |
| Date of last physician encounter | ||
| Recent (2017–2018) | 40 (58%) | 60 (41.4%) |
| Intermediate (2015–2016) | 18 (26.1%) | 52 (35.9%) |
| Distant (2013–2014) | 11 (15.9%) | 33 (22.7%) |
| Allied health encounter | 32 (46.3%) | 55 (38%) |
| According to date of last physician encounter | ||
| Recent (2017–2018) | 17/40 (42.5%) | 18/60 (30%) |
| Intermediate (2015–2016) | 7/18 (38.9%) | 23/52 (44.2%) |
| Distant (2013–2015) | 8/11 (72.7%) | 14/33 (42.4%) |
Characteristics of the 69 participants who responded to the satisfaction survey
| Characteristic | Survey responders |
|---|---|
| Age—mean in years (SD) | 66 (12.3) |
| Sex | |
| Male | 4 (5.8) |
| Female | 65 (94.2) |
| History of fragility fracture(s) | |
| None | 33 (47.8) |
| One | 11 (15.9) |
| Two or more | 15 (21.7) |
| Unknown | 10 (14.5) |
| Fracture risk category | |
| Low | 9 (13.0) |
| Moderate | 23 (33.3) |
| Moderate-to-high | 2 (2.9) |
| High | 20 (29) |
| Unknown | 15 (21.7) |
| Osteoporosis medication at time of initial consult | |
| None | 36 (52.2) |
| Risedronate | 15 (21.7) |
| Alendronate | 4 (5.8) |
| Zoledronic acid | 1 (1.4) |
| Denosumab | 3 (4.3) |
| Unknown | 10 (14.5) |
| Co-morbidities | |
| None | 9 (13.0) |
| One | 9 (13.0) |
| Two or more | 41 (59.4) |
| Unknown | 10 (14.5) |
Survey results from the 69 participants who completed the satisfaction survey
| Survey question | Survey responses | ||||||
|---|---|---|---|---|---|---|---|
| Strongly agree | Agree | Neutral | Disagree | Strongly disagree | Not applicable | No response | |
| The instructions in the appointment package were clear and easy to follow. | 34 (49) | 25 (36) | 4 (6) | 1 (1) | 0 (0) | 4 (6) | 1 (1) |
| I was satisfied with the wait time for my initial Telemedicine appointment. | 32 (46) | 23 (33) | 5 (7) | 6 (9) | 2 (3) | 1 (1) | 0 (0) |
| I was satisfied with the information I received about my bone health concerns at my Telemedicine appointment. | 33 (48) | 27 (39) | 4 (6) | 2 (3) | 1 (1) | 1 (1) | 1 (1) |
| I feel that the | 39 (57) | 21 (30) | 3 (4) | 3 (4) | 1 (1) | 0 (0) | 2 (3) |
| My tests (such as bone density, lab-work and x-ray) were well coordinated with my Telemedicine appointment. | 36 (52) | 16 (23) | 6 (9) | 5 (7) | 4 (6) | 1 (1) | 1 (1) |
| The recommendations and plans suggested by the doctor regarding my bone health were clear. | 37 (54) | 19 (28) | 6 (9) | 2 (3) | 2 (3) | 2 (3) | 1 (1) |
| The following allied health care providers were helpful: | |||||||
| Pharmacist | 11 (16) | 4 (6) | 2 (3) | 2 (3) | 0 (0) | 32 (46) | 15 (22) |
| Occupational therapist | 5 (7) | 5 (7) | 3 (4) | 1 (1) | 0 (0) | 33 (48) | 21 (30) |
| Physical therapist | 9 (13) | 4 (6) | 1 (1) | 3 (4) | 1 (1) | 32 (46) | 18 (26) |
| Athletic therapist | 10 (14) | 3 (4) | 2 (3) | 2 (3) | 1 (1) | 30 (43) | 20 (29) |
| Dietician | 11 (16) | 7 (10) | 2 (3) | 2 (3) | 0 (0) | 30 (43) | 16 (23) |
| Nurse | 16 (23) | 8 (12) | 3 (4) | 3 (4) | 0 (0) | 27 (39) | 13 (19) |
| I am comfortable with my personal health information being assessed by Telemedicine. | 35 (51) | 21 (30) | 7 (10) | 1 (1) | 0 (0) | 2 (3) | 3 (4) |
| I would be interested in using the following technologies to enhance my future telemedicine appointments: | |||||||
| My personal computer | 23 (33) | 10 (14) | 4 (6) | 1 (1) | 2 (3) | 13 (19) | 15 (22) |
| My mobile device | 8 (12) | 4 (6) | 1 (1) | 4 (6) | 3 (4) | 16 (23) | 32 (46) |
Characteristics of the 15 participants who were interviewed. Date of last physician encounter is categorized as “Recent” if the participant was last seen within 1 year of the survey mail-out from 2017 to 2018, “Intermediate” if last seen between 2015 and 2016, and “Distant” if last seen between 2013 and 2014. Allied health encounter data is presented if the participant had a minimum of one visit encounter with an allied health team member
| Characteristic | Interviewed participants |
|---|---|
| Age—mean in years (SD) | 68 (12.5) |
| Sex | |
| Male | 1 (6.7) |
| Female | 14 (93.3) |
| History of fragility fracture(s) | |
| None | 6 (40.0) |
| One | 0 (0) |
| Two or more | 8 (53.3) |
| Unknown | 1 (6.7) |
| Fracture risk category | |
| Low | 0 (0) |
| Moderate | 4 (26.7) |
| Moderate-to-high | 1 (6.7) |
| High | 7 (46.7) |
| Unknown | 3 (20.0) |
| Osteoporosis medication at time of initial cconsult | |
| None | 5 (33.3) |
| Risedronate | 6 (40.0) |
| Alendronate | 1 (6.7) |
| Zoledronic acid | 0 (0) |
| Denosumab | 2 (13.3) |
| Unknown | 1 (6.7) |
| Co-morbidities | |
| None | 0 (0) |
| One | 3 (20.0) |
| Two or more | 11 (73.3) |
| Unknown | 1 (6.7) |
| Completed survey | |
| Yes | 8 (53.3) |
| No | 7 (46.7) |
| Date of last physician encounter | |
| Recent (2017–2018) | 11 (73.3) |
| Intermediate (2015–2016) | 2 (13.3) |
| Distant (2013–2014) | 2 (13.3) |
| Allied health encounter | |
| Yes | 2 (13.3) |
| No | 13 (84.6) |